Step into the Future
Pluri Launches Sustainable Cell-Based Coffee as Countermeasure for Global Coffee Crisis - Seite 2
Pluri’s goal is to spin out its cell-based coffee as a new subsidiary focused on developing innovative products, technologies and intellectual property for the coffee industry. This new planned subsidiary will be led by Michal Ogolnik, a dynamic, results-driven business leader. She has over 20 years of executive management experience in the pharma and energy sectors.
“We are uniquely positioned to transform the coffee industry with our sustainable cell-based coffee,” said Michal Ogolnik. “By harnessing the power of Pluri’s cutting-edge technology, we could create a brighter, more sustainable future for our planet. By bringing innovation to the forefront, we can tackle some of the coffee industry’s most pressing challenges.”
“We believe deeply in the power of cell technology to make farming and food cultivation more productive and sustainable. Pluri’s advanced agtech solutions potentially reduce the environmental footprint of traditional agricultural production. PluriAgtech can deliver numerous solutions ranging from products like cell-based coffee to bioactive in order to address the biggest challenges in agriculture,” said Pluri CEO and President Yaky Yanay. “We see great interest in the development of additional cell-based products under the PluriAgtech vertical from potential partners. We are excited about the opportunities presented by cell-based coffee.”
To learn more about Pluri’s cell-based coffee visit our website.
About Pluri Inc.
Lesen Sie auch
Pluri is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global well-being and sustainability. The Company’s technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of challenges— from medicine and climate change to food scarcity, animal cruelty and beyond. Pluri’s method is uniquely accurate, scalable, cost-effective and consistent from batch to batch. Pluri currently operates in the field of regenerative medicine, food-tech, agtech and biologics and offers CDMO services. Pluri establishes partnerships that leverage the Company’s proprietary 3D cell-based technology across various industries that require effective, mass cell production. To learn more, visit us at www.pluri-biotech.com or follow Pluri on LinkedIn and X (formerly known as Twitter).